Smoldering multiple myeloma requiring treatment: time for a new definition?
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Smoldering multiple myeloma requiring treatment: time for a new definition?
Authors
Keywords
-
Journal
BLOOD
Volume 122, Issue 26, Pages 4172-4181
Publisher
American Society of Hematology
Online
2013-10-22
DOI
10.1182/blood-2013-08-520890
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
- (2013) S V Rajkumar et al. LEUKEMIA
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Total cost comparison in relapsed/refractory multiple myeloma
- (2013) Brian Durie et al. JOURNAL OF MEDICAL ECONOMICS
- Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study
- (2012) Terry Golombick et al. AMERICAN JOURNAL OF HEMATOLOGY
- Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
- (2012) S. Z. Usmani et al. BLOOD
- Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form
- (2012) Angela Rago et al. CANCER
- Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: A comparison of results in different phases of the disease
- (2012) P. Spinnato et al. EUROPEAN JOURNAL OF RADIOLOGY
- Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
- (2012) P Falco et al. LEUKEMIA
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
- (2012) G Bianchi et al. LEUKEMIA
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
- (2012) T E Witzig et al. LEUKEMIA
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
- (2012) J T Larsen et al. LEUKEMIA
- Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
- (2012) E Kastritis et al. LEUKEMIA
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
- (2011) Shaji K. Kumar et al. CANCER
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
- (2011) Giovanni D'arena et al. LEUKEMIA & LYMPHOMA
- Treatment of multiple myeloma
- (2011) S. Vincent Rajkumar Nature Reviews Clinical Oncology
- Diagnosis of Smoldering Multiple Myeloma
- (2011) S. Vincent Rajkumar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data
- (2011) D. Pulte et al. ONCOLOGIST
- Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
- (2010) Kristen Detweiler-Short et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
- (2010) G. Bianchi et al. BLOOD
- Incidence and follow-up of asymptomatic multiple myeloma.
- (2010) F. Wisløff et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
- (2010) Martin Hjorth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma
- (2010) Heinz Ludwig et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma Cell Labeling Index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma
- (2010) Sumit Madan et al. MAYO CLINIC PROCEEDINGS
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
- (2008) B. Barlogie et al. BLOOD
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
- (2008) Pellegrino Musto et al. CANCER
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started